European equities traded in the US as American depositary receipts were climbing higher Thursday morning, rising 1.19% to 1,475.61 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk (NVO) and semiconductor company Sequans Communications (SQNS), which rose 6.2% and 4.3% respectively. They were followed by EDAP TMS (EDAP) and biopharmaceutical company Genfit (GNFT), which were up 4.3% and 3.9% respectively. medical device maker
The decliners from continental Europe were led by internet advertising firm Criteo (CRTO) and telecommunications operator Telefonica (TEF), which were down 1.9% and 0.7% respectively. They were followed by internet browser company Opera (OPRA) and oil and gas company Eni (E), which lost 0.7% and 0.6% respectively.
From the UK and Ireland, the gainers were led by hospitality company InterContinental Hotels Group (IHG) and biopharmaceutical companies Biodexa Pharmaceuticals (BDRX), which increased 7% and 5.1% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and Adaptimmune Therapeutics (ADAP), which advanced 4.3% and 2.9% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and pharmaceutical company Silence Therapeutics (SLN), which dropped 7.7% and 1.9% respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and communications company WPP (WPP), which fell 1.9% each.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.